SecBot SecBot
SECBOTREPLAY Home › Report › SKYE

SKYE · Skye Bioscience received a Nasdaq delisting notice on May 13, 2026, for…

Skye Bioscience, Inc. · 8-K filed May 15, 2026 at 16:00 ET

At the news

BEARISHIMPACT 7/10

8-K filed May 15, 2026 at 16:00 ET

Skye Bioscience received a Nasdaq delisting notice on May 13, 2026, for failing to meet the $10M minimum stockholders' equity requirement (reported equity: $9,011,804). The company has 45 days to submit a compliance plan, with a possible 180-day extension to cure. Failure to regain compliance could result in delisting from the Nasdaq Global Market, severely impacting liquidity and institutional ownership.

  • Stockholders' equity was $9,011,804 as of March 31, 2026, below the $10,000,000 minimum required by Nasdaq Listing Rule 5450(b)(1)(A).
  • Company has until June 29, 2026 to submit a compliance plan to Nasdaq.
  • If plan is accepted, Nasdaq may grant an extension until November 9, 2026 to regain compliance.
  • No immediate effect on trading; stock continues to trade under symbol SKYE.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access